Key Focus for Legend Biotech Investors

By Susan Ramirez • Wednesday, January 24 08:50 • Permanent Link

Legend Biotech marked a 8.2% change today. Is it a good value at today's price of $60.79? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally.
Legend Biotech belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
The company's P/B ratio is 8.25
Legend Biotech has a trailing 12 month Price to Earnings (P/E) ratio of -20.5 based on its trailing 12 month price to earnings (EPS) of $-2.96 per share
Its forward P/E ratio is -34.9, based on its forward earnings per share (EPS) of $-1.74
Over the last four years, Legend Biotech has averaged free cash flows of $-115960833.3, which on average grew -15.9%
Legend Biotech has moved 14.2% over the last year compared to 21.1% for the S&P 500 -- a difference of -7.0%
LEGN has an average analyst rating of buy and is -29.66% away from its mean target price of $86.42 per share

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.